2. For patients with newly diagnosed sJIA presenting predominantly with systemic features and high disease activity, initiate treatment with a bDMARD targeting the IL-1 pathway (anakinra, canakinumab or rilonacept) or the IL-6 receptor (tocilizumab) as first-line therapy. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.